Phase I, prospective, open-label, limited-center pharmacokinetic (PK) interaction study designed to compare the PK of TMC207 given alone with the PK of TMC207 given concomitantly with EFV and to evaluate the safety and tolerability of TMC207 given together with EFV. This protocol completed enrollment and follow-up in December 2010.